Logo

CuraGen, Pfizer in Toxicogenomics Deal

Jan 07, 2003

NEW YORK, Jan. 7-CuraGen is working with Pfizer to apply toxicogenomics screening and protein pathway mapping for the pharmaceutical company's drug candidates, CuraGen said today.

 

CuraGen researchers will use the company's Predictive Toxicogenomics Screen early on in the drug development process to select promising compounds. The company will also supply its protein pathway mapping techniques to explore mechanisms and activity of drugs in later development stages.

 

Financial details of the agreement were not disclosed.

 

For further information, see the press release.

Breaking News
The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.